Washington, DC (UroToday.com) Nikolaus Schultz from Memorial Sloan Kettering discussed the MSK IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets). While this is promising work towards precision-based medicine he mentioned most mutations identified are passenger mutations which are not relevant but ‘along for the ride’. However, IMPACT can infer tumor mutational burden to identify the driver and actionable variants.
He reviewed cancer hot spots and used the ERBB2 mutation pattern as an example to identify which genes are more commonly mutated. ERBB2 hotspots in bladder cancer were reviewed with over half mutations identified in known hotspots. Importantly, we need improved dissemination of variant knowledge as we move forward with identified actionable variants for clinical trials and overall clinical application in the future. He reviewed MSK-IMPACT reports to enhance the dissemination of this knowledge to make genomic information transferrable and easily understandable for clinical application.
Presented by: Nikolaus Schultz, Ph.D., Head of Knowledge Systems, Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering, New York, New York
Written by: Stephen B. Williams, MD, Medical Director for High Value Care; Chief of Urology, Associate Professor, Director of Urologic Oncology, Director Urologic Research, The University of Texas Medical Branch at Galveston, TX and Ashish M. Kamat, MD, Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 2019 Bladder Cancer Advocacy Network (BCAN) Think Tank August 8-10, 2019 – the Capital Hilton, Washington, DC, USA